13 Jan 2022
Allergy Therapeutics - Half-year trading update
The six-month trading update to 31 December reflects the discontinuation of non-core products, ongoing COVID-19-related headwinds, principally in Germany and Italy, exchange-rate headwinds (-5%) and product phasing issues, with revenues falling 10% to £48.7m. Underlying like-for-like growth, however, was 3% at constant exchange rates (CER). Period-end cash was £41.4m, which implied a c.3% increase (+£1.m) in underlying cashflows in the period. We have reduced revenue forecasts by 9% in FY 2022 t ....
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Allergy Therapeutics - Half-year trading update
Allergy Therapeutics plc (AGY:LON) | 11.5 0 (-1.7%) | Mkt Cap: 706.3m
- Published:
13 Jan 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12 -
The six-month trading update to 31 December reflects the discontinuation of non-core products, ongoing COVID-19-related headwinds, principally in Germany and Italy, exchange-rate headwinds (-5%) and product phasing issues, with revenues falling 10% to £48.7m. Underlying like-for-like growth, however, was 3% at constant exchange rates (CER). Period-end cash was £41.4m, which implied a c.3% increase (+£1.m) in underlying cashflows in the period. We have reduced revenue forecasts by 9% in FY 2022 t ....